Commercial Marketing interview prep.
Brand directors, marketing managers, launch leads, market access + HEOR (health economics + outcomes research), sales ops.
What interviewers look for
- Can the candidate build a brand strategy grounded in clinical evidence + patient + HCP insight?
- Do they understand market access + payer realities - formulary, prior auth, payer evidence asks, HEOR?
- Are they fluent in HCP + patient + payer audiences + their distinct drivers?
- Can they lead a cross-functional launch - field, medical, market access, commercial ops, compliance, legal?
- Do they navigate compliance + regulatory constraints (PhRMA Code, OIG, off-label, PDUFA) without becoming paralysed?
- Are they fluent in lifecycle thinking - LOE response, label expansion, biosimilar / generic competition?
- Can they show evidence-based decision-making + comfort with the data even when the answer's hard?
Behavioural questions to expect
Walk me through your background + commercial experience.
What it tests: Story arc - relevant training (MBA / clinical / scientific), commercial / brand exposure, matrix experience.
Tell me about a brand or launch you've led or significantly contributed to.
What it tests: Commercial thinking - strategy, evidence-narrative connection, cross-functional execution, measurable outcome.
Why pharma commercial + brand vs other commercial paths (FMCG, tech, consulting)?
What it tests: Authentic alignment - patient impact, evidence-driven storytelling, complex multi-stakeholder.
Why this therapeutic area?
What it tests: Specificity. Generic answers fail.
Why this firm?
What it tests: Real homework - portfolio, recent moves, commercial culture - not name-drop.
What's your read on our commercial portfolio + recent launches?
What it tests: Industry literacy - asset performance, share, growth, competitive position.
Tell me what you understand about our market access + payer strategy.
What it tests: Market access fluency - formulary position, payer contracting, HEOR + RWE investment.
Walk me through positioning + brand strategy for a specific asset.
What it tests: Brand strategy thinking - patient + HCP insight + clinical evidence + competitive context = positioning.
Technical concepts to master
Positioning + evidence linkage
- Patient + HCP insight
- Qualitative + quantitative research into disease experience, decision drivers, unmet needs - foundation of strategy.
- Clinical evidence translation
- Translating clinical trial + RWE + HEOR into language + claims that HCP + patient + payer find compelling.
- Positioning statement
- Compact statement of [target audience], [core benefit], [reason-to-believe], [competitive context].
- Reason to believe (RTB)
- Specific evidence + features supporting the positioning claim.
Market access + payer strategy
- Payer archetypes
- Commercial payers, Medicare (Part B + D + MA), Medicaid, VA / DoD - distinct decision drivers + evidence asks.
- Formulary decision + P&T
- Pharmacy + Therapeutics Committee at payer reviews evidence + cost + outcomes to set formulary position.
- Gross-to-net
- Difference between list price + actual net realised - rebates, 340B, Medicaid, patient assistance, distribution fees.
- Contracting + rebate strategy
- Negotiated rebates with payers in exchange for preferred formulary or removed restrictions.
HEOR + RWE
- HEOR (Health Economics + Outcomes Research)
- Modelling cost-effectiveness, budget impact, productivity, quality of life - generates evidence payers + HTA bodies need.
- Real-world evidence (RWE)
- Evidence from healthcare data - claims, EHR, registry, patient-generated - on effectiveness + safety + utilisation.
- ICER + value frameworks
- Institute for Clinical + Economic Review - independent US value framework; NICE in UK; CADTH in Canada.
- Patient-reported outcomes (PROs)
- Patient-reported measures (HRQoL, symptom, function) supporting clinical + commercial evidence.
Compliance + PhRMA Code
- PhRMA Code on Interactions with HCPs
- Industry voluntary code governing HCP interactions - meals, education, samples, gifts.
- Off-label communication restrictions
- FDA restricts promotion to on-label use; off-label discussions allowed in unsolicited medical inquiry context via Med Affairs.
- OIG + DOJ enforcement
- OIG Office of Inspector General + DOJ enforce anti-kickback + False Claims Act on pharma.
- Open Payments + Sunshine Act
- Federal requirement to publicly report payments + transfers of value to HCPs.
Practical drills
- You're the new brand lead for an asset just approved in a competitive market with 3 established competitors. Walk through your positioning strategy.
- Your asset is 9 months from PDUFA. Walk through your pre-launch + launch plan - cross-functional sequencing + KPIs.
- A major commercial payer just moved your asset from preferred to non-preferred, citing inadequate evidence vs comparator. Walk through your response.
Smart-question anchors
- Portfolio + recent launches - asset performance, competitive position
- Commercial org + matrix - brand / TA structure, cross-functional alignment
- Market access posture - HEOR investment, contracting model, recent access events
- Patient + HCP engagement - omni-channel, DTC, hub + services investment
- Compliance + ethics culture - PhRMA Code adherence, recent enforcement experience
Related roles
Sourced from
Ready to Generate Your Own Prep?
Drop your CV and a job description on the home page. A couple of minutes later you get a report with everything you need to land the job.